Deutsche Bank
ELVN icon

Deutsche Bank’s Enliven Therapeutics ELVN Stock Holding History

Deutsche Bank’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.29M Buy
45,109
+9,790
+28% +$416K ﹤0.01% 1832
2026
Q1 		$1.38M Buy
35,319
+3,899
+12% +$108K ﹤0.01% 1991
2025
Q4 		$484K Buy
31,420
+6,231
+25% +$124K ﹤0.01% 2586
2025
Q3 		$516K Buy
25,189
+2,714
+12% +$54.7K ﹤0.01% 2520
2025
Q2 		$451K Sell
22,475
-5,049
-18% -$95.6K ﹤0.01% 2510
2025
Q1 		$542K Sell
27,524
-2,992
-10% -$64.4K ﹤0.01% 2452
2024
Q4 		$687K Buy
30,516
+10,397
+52% +$270K ﹤0.01% 2454
2024
Q3 		$514K Buy
20,119
+4,868
+32% +$113K ﹤0.01% 2442
2024
Q2 		$356K Buy
15,251
+4,277
+39% +$90K ﹤0.01% 2517
2024
Q1 		$193K Buy
10,974
+343
+3% +$5.26K ﹤0.01% 2838
2023
Q4 		$147K Sell
10,631
-259
-2% -$3.17K ﹤0.01% 3034
2023
Q3 		$149K Buy
10,890
+1,559
+17% +$26.3K ﹤0.01% 2961
2023
Q2 		$190K Buy
+9,331
New +$189K ﹤0.01% 2906
2021
Q4 		– Sell
-25
Closed – – 4285
2021
Q3 		$0 Sell
25
-5,351
-100% -$111K ﹤0.01% 4463
2021
Q2 		$170K Buy
5,376
+2,531
+89% +$78.5K ﹤0.01% 3874
2021
Q1 		$96K Buy
2,845
+1,439
+102% +$73.1K ﹤0.01% 3997
2020
Q4 		$124K Buy
1,406
+714
+103% +$59.9K ﹤0.01% 3727
2020
Q3 		$56K Buy
692
+60
+9% +$5.41K ﹤0.01% 3835
2020
Q2 		$70K Buy
+632
New +$70.7K ﹤0.01% 3638

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deutsche Bank's ELVN Position: Q2 2026 in Review

Deutsche Bank increased its Enliven Therapeutics (ELVN) stake by 28% in Q2 2026, buying an estimated $416K and bringing the position to 45,109 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Deutsche Bank first reported a position in ELVN in Q2 2020 and has held it in 19 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Deutsche Bank held 45,109 shares of Enliven Therapeutics worth $2.29M as of Q2 2026.
  • Deutsche Bank bought 9,790 Enliven Therapeutics shares in Q2 2026, an estimated $416K.
  • Enliven Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1832 holding.
  • Deutsche Bank first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 19 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.